The CSL Limited (ASX: CSL) share price is flat at $198.60 today after the $90 billion healthcare giant gave a presentation to investors on the progress of its Seqirus influenza vaccine business at a Macquarie Group Ltd (ASX: MQG) organised equities conference in Sydney.
The flu business is seasonal as most patients receive their flu jabs in the northern hemisphere's autumn period ahead of the winter flu season and the below slide shows how Seqirus grew revenue 21% over the first half of fiscal 2019.
Total CSL revenue over the first half of fiscal 2019 was US$4,505 million so we can see that Seqirus at US$949 million is a significant and fast-growing profit driver for the business for its interim results.
However, it should be noted that over the second half the fixed cost base and lack of demand may result in Seqirus posting a loss for now.
Thanks to its multiple operating arms delivering consistent growth CSL remains one of the best looking blue-chip shares on the ASX, alongside its host today Macquarie Group.
